产品: | DDX58 抗体 |
货号: | DF6107 |
描述: | Rabbit polyclonal antibody to DDX58 |
应用: | WB IHC |
反应: | Human, Mouse, Rat |
预测: | Pig, Bovine, Horse, Sheep, Rabbit, Dog |
分子量: | 107kDa; 107kD(Calculated). |
蛋白号: | O95786 |
RRID: | AB_2838075 |
产品描述
*The optimal dilutions should be determined by the end user.
*Tips:
WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.
引用格式: Affinity Biosciences Cat# DF6107, RRID:AB_2838075.
展开/折叠
Ddx58; DDX58_HUMAN; DEAD (Asp Glu Ala Asp) box polypeptide 58; DEAD (Asp Glu Ala Asp/His) box polypeptide; DEAD box protein 58; DEAD/H (Asp Glu Ala Asp/His) box polypeptide RIG1; DKFZp434J1111; DKFZp686N19181; FLJ13599; Probable ATP dependent RNA helicase DDX58; Probable ATP-dependent RNA helicase DDX58; Retinoic acid inducible gene 1 protein; Retinoic acid-inducible gene 1 protein; Retinoic acid-inducible gene I protein; RIG I; Rig-1; RIG-I; RIG1; rigi; RLR 1; RNA helicase; RNA helicase RIG I; SGMRT2;
抗原和靶标
- O95786 DDX58_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MTTEQRRSLQAFQDYIRKTLDPTYILSYMAPWFREEEVQYIQAEKNNKGPMEAATLFLKFLLELQEEGWFRGFLDALDHAGYSGLYEAIESWDFKKIEKLEEYRLLLKRLQPEFKTRIIPTDIISDLSECLINQECEEILQICSTKGMMAGAEKLVECLLRSDKENWPKTLKLALEKERNKFSELWIVEKGIKDVETEDLEDKMETSDIQIFYQEDPECQNLSENSCPPSEVSDTNLYSPFKPRNYQLELALPAMKGKNTIICAPTGCGKTFVSLLICEHHLKKFPQGQKGKVVFFANQIPVYEQQKSVFSKYFERHGYRVTGISGATAENVPVEQIVENNDIIILTPQILVNNLKKGTIPSLSIFTLMIFDECHNTSKQHPYNMIMFNYLDQKLGGSSGPLPQVIGLTASVGVGDAKNTDEALDYICKLCASLDASVIATVKHNLEELEQVVYKPQKFFRKVESRISDKFKYIIAQLMRDTESLAKRICKDLENLSQIQNREFGTQKYEQWIVTVQKACMVFQMPDKDEESRICKALFLYTSHLRKYNDALIISEHARMKDALDYLKDFFSNVRAAGFDEIEQDLTQRFEEKLQELESVSRDPSNENPKLEDLCFILQEEYHLNPETITILFVKTRALVDALKNWIEGNPKLSFLKPGILTGRGKTNQNTGMTLPAQKCILDAFKASGDHNILIATSVADEGIDIAQCNLVILYEYVGNVIKMIQTRGRGRARGSKCFLLTSNAGVIEKEQINMYKEKMMNDSILRLQTWDEAVFREKILHIQTHEKFIRDSQEKPKPVPDKENKKLLCRKCKALACYTADVRVIEECHYTVLGDAFKECFVSRPHPKPKQFSSFEKRAKIFCARQNCSHDWGIHVKYKTFEIPVIKIESFVVEDIATGVQTLYSKWKDFHFEKIPFDPAEMSK
种属预测
score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。
High(score>80) Medium(80>score>50) Low(score<50) No confidence
翻译修饰 - O95786 作为底物
Site | PTM Type | Enzyme | Source |
---|---|---|---|
S8 | Phosphorylation | P05771 (PRKCB) , P17252 (PRKCA) | Uniprot |
Y40 | Phosphorylation | Uniprot | |
K45 | Ubiquitination | Uniprot | |
K96 | Sumoylation | Uniprot | |
K96 | Ubiquitination | Uniprot | |
K99 | Ubiquitination | Uniprot | |
K115 | Ubiquitination | Uniprot | |
K146 | Ubiquitination | Uniprot | |
K154 | Ubiquitination | Uniprot | |
K164 | Ubiquitination | Uniprot | |
K169 | Ubiquitination | Uniprot | |
T170 | Phosphorylation | P05771 (PRKCB) , P17252 (PRKCA) | Uniprot |
K172 | Ubiquitination | Uniprot | |
K177 | Ubiquitination | Uniprot | |
K181 | Ubiquitination | Uniprot | |
K190 | Ubiquitination | Uniprot | |
K193 | Ubiquitination | Uniprot | |
T197 | Phosphorylation | Uniprot | |
K256 | Ubiquitination | Uniprot | |
K258 | Ubiquitination | Uniprot | |
K292 | Ubiquitination | Uniprot | |
K307 | Ubiquitination | Uniprot | |
K312 | Ubiquitination | Uniprot | |
K455 | Ubiquitination | Uniprot | |
K458 | Ubiquitination | Uniprot | |
S468 | Phosphorylation | Uniprot | |
Y473 | Phosphorylation | Uniprot | |
K491 | Ubiquitination | Uniprot | |
K561 | Ubiquitination | Uniprot | |
K568 | Ubiquitination | Uniprot | |
K593 | Ubiquitination | Uniprot | |
K644 | Ubiquitination | Uniprot | |
K652 | Ubiquitination | Uniprot | |
S654 | Phosphorylation | Uniprot | |
K657 | Ubiquitination | Uniprot | |
K666 | Ubiquitination | Uniprot | |
T667 | Phosphorylation | Uniprot | |
T671 | Phosphorylation | Uniprot | |
T674 | Phosphorylation | Uniprot | |
K679 | Ubiquitination | Uniprot | |
K757 | Ubiquitination | Uniprot | |
K759 | Ubiquitination | Uniprot | |
S764 | Phosphorylation | Uniprot | |
T770 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
K779 | Ubiquitination | Uniprot | |
K788 | Ubiquitination | Uniprot | |
K796 | Ubiquitination | Uniprot | |
K798 | Ubiquitination | Uniprot | |
K812 | Ubiquitination | Uniprot | |
K851 | Ubiquitination | Uniprot | |
S854 | Phosphorylation | P68400 (CSNK2A1) | Uniprot |
S855 | Phosphorylation | Q14164 (IKBKE) , P68400 (CSNK2A1) | Uniprot |
K858 | Acetylation | Uniprot | |
K858 | Ubiquitination | Uniprot | |
Y879 | Phosphorylation | Uniprot | |
K880 | Ubiquitination | Uniprot | |
K888 | Sumoylation | Uniprot | |
K909 | Acetylation | Uniprot | |
K909 | Ubiquitination | Uniprot | |
K915 | Ubiquitination | Uniprot |
研究背景
Innate immune receptor that senses cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and proinflammatory cytokines. Forms a ribonucleoprotein complex with viral RNAs on which it homooligomerizes to form filaments. The homooligomerization allows the recruitment of RNF135 an E3 ubiquitin-protein ligase that activates and amplifies the RIG-I-mediated antiviral signaling in an RNA length-dependent manner through ubiquitination-dependent and -independent mechanisms. Upon activation, associates with mitochondria antiviral signaling protein (MAVS/IPS1) that activates the IKK-related kinases TBK1 and IKBKE which in turn phosphorylate the interferon regulatory factors IRF3 and IRF7, activating transcription of antiviral immunological genes including the IFN-alpha and IFN-beta interferons. Ligands include 5'-triphosphorylated ssRNAs and dsRNAs but also short dsRNAs (<1 kb in length). In addition to the 5'-triphosphate moiety, blunt-end base pairing at the 5'-end of the RNA is very essential. Overhangs at the non-triphosphorylated end of the dsRNA RNA have no major impact on its activity. A 3'overhang at the 5'triphosphate end decreases and any 5'overhang at the 5' triphosphate end abolishes its activity. Detects both positive and negative strand RNA viruses including members of the families Paramyxoviridae: Human respiratory syncytial virus and measles virus (MeV), Rhabdoviridae: vesicular stomatitis virus (VSV), Orthomyxoviridae: influenza A and B virus, Flaviviridae: Japanese encephalitis virus (JEV), hepatitis C virus (HCV), dengue virus (DENV) and west Nile virus (WNV). It also detects rotaviruses and reoviruses. Also involved in antiviral signaling in response to viruses containing a dsDNA genome such as Epstein-Barr virus (EBV). Detects dsRNA produced from non-self dsDNA by RNA polymerase III, such as Epstein-Barr virus-encoded RNAs (EBERs). May play important roles in granulocyte production and differentiation, bacterial phagocytosis and in the regulation of cell migration.
(Microbial infection) Deamidated on 'Asn-495' and 'Asn-549' by herpes simplex virus 1 protein UL37. These modifications eliminate DDX58 detection of viral RNA and restriction of viral replication.
(Microbial infection) Cleaved by the protease 3C of coxsackievirus B3, poliovirus and enterovirus 71 allowing the virus to disrupt the host type I interferon production.
Phosphorylated in resting cells and dephosphorylated in RNA virus-infected cells. Phosphorylation at Thr-770, Ser-854 and Ser-855 results in inhibition of its activity while dephosphorylation at these sites results in its activation.
ISGylated. Conjugated to ubiquitin-like protein ISG15 upon IFN-beta stimulation. ISGylation negatively regulates its function in antiviral signaling response.
Sumoylated, probably by MUL1; inhibiting its polyubiquitination.
Ubiquitinated. 'Lys-63' ubiquitination by RNF135, which occurs after RNA-binding and homodimerization, releases the autoinhibition of the CARD domains by the RLR CTR domain, an essential step in the activation of the RIG-I signaling pathway. Lys-172 is the critical site of ubiquitination for MAVS/IPS1 binding and to induce anti-viral signal transduction. Lys-154, Lys-164 and Lys-172 are shared sites for RNF135-mediated and TRIM4-mediated ubiquitination. Also undergoes 'Lys-48' ubiquitination at Lys-181 by RNF125 that leads to proteasomal degradation. 'Lys-48' ubiquitination follows viral infection and is enhanced by 'Lys-63'-linked ubiquitination of the CARD domains that promotes interaction with VCP/p97 and subsequent recruitment of RNF125. Within a negative feedback loop involving SIGLEC10 and PTPN11, 'Lys-48' ubiquitination at Lys-812 by CBL also elicits the proteasomal degradation of DDX58 (By similarity). Deubiquitinated by CYLD, a protease that selectively cleaves 'Lys-63'-linked ubiquitin chains. Also probably deubiquitinated by USP17L2/USP17 that cleaves 'Lys-48'- and 'Lys-63'-linked ubiquitin chains and positively regulates the receptor.
Cytoplasm. Cell projection>Ruffle membrane. Cytoplasm>Cytoskeleton. Cell junction>Tight junction.
Note: Colocalized with TRIM25 at cytoplasmic perinuclear bodies. Associated with the actin cytoskeleton at membrane ruffles.
Present in vascular smooth cells (at protein level).
Monomer; maintained as a monomer in an autoinhibited state. Upon binding of viral RNAs and conformational shift, homooligomerizes and forms filaments on these molecules. Interacts (via tandem CARD domain) with MAVS/IPS1 promoting its filamentation. Interacts with DHX58/LGP2, IKBKE, TBK1 and STING1. Interacts (via CARD domain) with TRIM25 (via SPRY domain). Interacts (double-stranded RNA-bound oligomeric form) with RNF135 (homodimer); involved in RNA length-dependent activation of the RIG-I signaling pathway. Interacts with CYLD. Interacts with NLRC5; blocks the interaction of MAVS/IPS1 to DDX58. Interacts with SRC. Interacts with DDX60. Interacts with isoform 2 of ZC3HAV1 (via zinc-fingers) in an RNA-dependent manner. Interacts (via tandem CARD domain) with SEC14L1; the interaction is direct and impairs the interaction of DDX58 with MAVS/IPS1. Interacts with VCP/p97; interaction is direct and allows the recruitment of RNF125 and subsequent ubiquitination and degradation. Interacts with NOP53; may regulate DDX58 through USP15-mediated 'Lys-63'-linked deubiquitination. Interacts with SIGLEC10, CBL and PTPN11; within a negative feedback loop leading to DDX58 degradation (By similarity). Interacts with LRRC25. Interacts with ZCCHC3; leading to activation of DDX58/RIG-I. Interacts with RNF123. Interacts with UBE2D3 and UBE2N; E2 ubiquitin ligases involved in RNF135-mediated ubiquitination of DDX58 and activation of the RIG-I signaling pathway. Interacts with IFIT3.
(Microbial infection) Interacts with protein Z of Guanarito virus, Machupo virus, Junin arenavirus and Sabia virus. This interaction disrupts its interaction with MAVS/IPS1, impeding downstream IRF3 and NF-kappa-B activation and resulting in decreased IFN-beta induction.
(Microbial infection) Interacts (via CARD domain) with Human respiratory syncytial virus A non-structural protein 2 (NS2) and this interaction disrupts its interaction with MAVS/IPS1, impeding downstream IRF3 activation.
(Microbial infection) Interacts with Rotavirus A non-structural protein 1 (NSP1) and this interaction induces down-regulation of DDX58/RIG-I.
(Microbial infection) Interacts with herpes simplex virus 1 protein US11; this interaction prevents the interaction of MAVS/IPS1 to DDX58.
(Microbial infection) Interacts with herpes simplex virus 1 protein UL37; this interaction deaminates DDX58 and inhibits its activation.
The RLR CTR domain controls homooligomerization and interaction with MAVS/IPS1. In the absence of viral infection, the protein is maintained as a monomer in an autoinhibited state with the CARD domains masked through intramolecular interactions with the RLR CTR domain. Upon binding to viral RNA and ubiquitination by RNF135, a conformational change releases the autoinhibition promoting further homooligomerization, interaction of the CARD domains with the adapter protein MAVS/IPS1 and activation of the downstream RIG-I signaling pathway.
The helicase domain is responsible for dsRNA recognition.
The 2 CARD domains are responsible for interaction with and signaling through MAVS/IPS1 and for association with the actin cytoskeleton.
The second CARD domain is the primary site for 'Lys-63'-linked ubiquitination.
Belongs to the helicase family. RLR subfamily.
研究领域
· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway. (View pathway)
· Human Diseases > Infectious diseases: Viral > Hepatitis C.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Viral > Measles.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.
· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.
· Organismal Systems > Immune system > RIG-I-like receptor signaling pathway. (View pathway)
· Organismal Systems > Immune system > Cytosolic DNA-sensing pathway. (View pathway)
限制条款
产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。
产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。
Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。产品仅供科学研究使用。不用于诊断和治疗。
产品未经授权不得转售。
Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.